Vitiligo-Like Secundary to Ribociclib: A Case Report
Main Article Content
Abstract
Ribociclib, a cyclin-dependent kinase (CDK) 4/6 inhibitor, is widely used in the treatment of metastatic breast cancer. However, its dermatologic adverse effects, particularly vitiligo-like lesions, have been recently reported. The pathomechanisms underlying these lesions remain unclear, but immune-mediated melanocyte destruction has been proposed. A literature review reveals an increasing number of similar cases, highlighting the need for further investigation into these adverse effects’ incidence, mechanisms, and clinical implications. We present a case of vitiligo-like depigmentation in a patient undergoing ribociclib therapy.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Anjaneyan G, Keechilat P, Duraisamy P, Eapen M. Ribociclib-induced extensive vitiligo-like lesions: possible pathomechanisms with clinical, dermoscopic and histological correlation. BMJ Case Rep. 2022;15(4):e248782.
II. Menteşoğlu D. Photoallergic dermatitis and vitiligo-like lesion in a patient with metastatic breast cancer using ribociclib. Indian J Pharmacol. 2023;55(3):190-191.
III. Kothari R, Darling HS, Bhatnagar A, Janney M, Mohan S, Kumar R. Ribociclib induced vitiligo-like lesions. Indian J Dermatol Venereol Leprol. 2024 Aug 30:1-2.
IV. Türkel A, Karaçin C, Öner İ, Şeyran E, Öksüzoğlu B. Vitiligo-like lesions associated with ribociclib in a woman with metastatic breast cancer. J Oncol Pharm Pract. 2023 Feb 9;0(0).
V. Sibaud V, Sollena P. Dermatologic toxicities to inhibitors of cyclin-dependent kinases CDK 4 and 6: An updated review for clinical practice. Ann Dermatol Venereol. 2023;150(3):208-212.
VI. Sharaf B, AlMasri R, Abdel-Razeq N, et al. Vitiligo-Like Lesions in a Patient with Metastatic Breast Cancer Treated with Cyclin-Dependent Kinase (CDK) 4/6 Inhibitor: A Case Report and Literature Review. Clin Cosmet Investig Dermatol. 2022;15:5-10.
VII. Chan OB, Su JC, Yazdabadi A, Chan A. Drug induced vitiligo-like depigmentation from a CDK 4/6 inhibitor. Asia Pac J Clin Oncol. 2022;18(2):e154-e156.
VIII. Silvestri M, Cristaudo A, Morrone A, et al. Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review. Drug Saf. 2021;44(7):725-732.
IX. Pasqualoni M, Orlandi A, Palazzo A, et al. Case report: Vitiligo-like toxicity due to ribociclib during first-line treatment of metastatic breast cancer: two cases of premature interruption of therapy and exceptional response. Front Oncol. 2023;13:1067264.
X. Bang AS, Fay CJ, LeBoeuf NR, et al. Multi-center retrospective review of vitiligo-like lesions in breast cancer patients treated with cyclin-dependent kinase 4 and 6 inhibitors. Breast Cancer Res Treat. 2024;204(3):643-647.
XI. Raschi E, Fusaroli M, La Placa M, et al. Skin Toxicities with Cyclin-Dependent Kinase 4/6 Inhibitors in Breast Cancer: Signals from Disproportionality Analysis of the FDA Adverse Event Reporting System. Am J Clin Dermatol. 2022;23(2):247-25